1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Diabetes and other endocrinal, nutritional and metabolic conditions
  5. Diabetes

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy

Technology appraisal guidance [TA301] Published date: 27 November 2013

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
  • Overview
  • 1 Guidance
  • 2 The technology
  • 3 The manufacturer's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Recommendations for further research
  • 7 Related NICE guidance
  • 8 Review of guidance
  • 9 Appraisal Committee members, guideline representatives and NICE project team
  • 10 Sources of evidence considered by the Committee
  • Changes after publication
  • About this guidance
  • Share
    • Share
    • Linked In
    • Twitter
    • Facebook
    • Email
    • More...
  • Download
    • Save
    • Save as PDF
    • Save as ePub
    • Save as eBook

Guidance

  • Next

Changes after publication

Changes after publication

July 2015: Cross reference to summary of product characteristics added to section 2.1.

  • National Institute for Health and Care Excellence (NICE)

  • Next